Activation of the interferon system is one of the important aspects in the treatment of clinical forms of human papillomavirus (HPV) infection that makes the use of nonspecific antiviral drugs justified in its recurrent course.

OBJECTIVE

Effectiveness evaluation of the immunomodulatory drug usage in the complex therapy of patients with recurrent anal-genital warts.

MATERIAL AND METHODS

Retrospective analysis of the treatment results of 78 patients with recurrent anal-genital warts: group 1 — 38 patients who underwent destruction of the rash; group 2 — 40 patients who underwent destruction in combination with an immunomodulatory drug (intramuscularly 200 IU on days 1, 2, 3, 8, 9, 10 of treatment). Quantitative determination of HPV genotypes was carried out before therapy and 6 months after its completion by real-time PCR.

RESULTS

Recurrences of anal-genital warts were registered in 8 (21.0%) patients of group 1: in 2 (5.26%) during the 1st month of observation, in 2 (5.26%) — at the 2nd or 3rd month, in 4 (10.5%) — at the 5-6th month of observation) and in 2 (5.0%) patients of group 2 at the 5-6th month of observation. Elimination of HPV was established in 4 (10.5%) patients of the 1st group and 13 (32.5%) patients of the 2nd group, a decrease in the quantitative parameters of HPV — in 62.9% and 23.5% of patients, respectively. In 1 (2.5%) patient of group 2, there was a complete regression of papillomatosis eruptions was noted, in 3 (7.5%) patients — a decrease in their number by more than 50% after 3 days of therapy with an immunomodulatory drug.

CONCLUSION

The inclusion of an immunomodulatory drug in the combined therapy of recurrent anal-genital warts is justified by its therapeutic efficacy in reducing the frequency of disease relapses and increasing the relapse-free interval, as well as a significant decrease in viral load and high rates of HPV elimination from lesions.